Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) has appointed Steven Tahmooressi as Vice President of Marketing as the company prepares to launch its first clinical kitted assay for transplant rejection testing in 2026. The strategic hire positions iMDx to capitalize on the estimated $1 billion addressable market for kitted transplant rejection testing through its GraftAssureDx diagnostic platform.
Executive Leadership Addition
Tahmooressi brings more than 25 years of healthcare industry experience to iMDx, with a proven track record in supporting the transplantation community across U.S. sales and marketing leadership to regional and global commercialization. He joins from Astellas Pharma, where he served as Global Brand Lead of Established Products Marketing covering transplant, urology and oncology brands. His career also includes commercial roles at Abbott Laboratories and Bristol-Myers Squibb.
"After three years of laser-focused investing in our kitted product for transplant rejection testing, we are now approaching the critical product launch phase of GraftAssureDx," said iMDx CEO Josh Riggs. "As we prepare for FDA authorization of GraftAssureDx next year, we are thrilled to welcome Steven to the team to lead our marketing efforts on this mission-critical product."
GraftAssure Technology Platform
The company's flagship transplant testing technology quantifies donor-derived cell-free DNA (dd-cfDNA), a molecular biomarker that has been established as a trusted indicator of transplant rejection. iMDx scientists in Germany and the U.S. have played a crucial role over the past decade in developing the science that helped establish dd-cfDNA as this biomarker.
The GraftAssure family of assays includes three distinct products:
GraftAssureCore serves as the company's laboratory-developed test (LDT), currently reimbursed by Medicare and performed at its CLIA-certified laboratory in Nashville. This represents a rebranding of the company's VitaGraft assay.
GraftAssureIQ became available for purchase in summer 2024 as a research-use-only (RUO) kit intended for non-clinical applications.
GraftAssureDx is the in vitro diagnostic (IVD) kit currently in development for clinical decision-making, which the company intends to submit for FDA authorization in 2025.
Market Opportunity and Clinical Impact
The clinical kitted version of the assay is designed to be distributed to hospitals to expand and improve testing access for kidney transplant patients. This approach represents what the company describes as a "market disruptive approach" to commercializing established dd-cfDNA technology.
"I am passionate about ensuring that patients and health care providers have access to the tools they need, and it's clear to me that iMDx is developing a product that will deliver value to the transplantation market," said Tahmooressi. "Since starting with the company in September, I have met with transplant physicians and HLA lab leads who have lauded the potential that iMDx transplant products can bring to their patients."
Commercial Preparation
Tahmooressi has already begun engaging with the transplantation community since joining iMDx in late September, including meeting with customers and supporting the company's presence at the annual meeting of the American Society of Histocompatibility & Immunogenetics in Orlando.
The appointment reflects iMDx's mission to democratize access to molecular diagnostic testing, with transplantation rejection testing serving as the company's first targeted strategic market. The company, formerly known as Oncocyte Corp., relocated its headquarters from Irvine, California, to Nashville, Tennessee, in June 2025, with its new NASDAQ symbol becoming effective June 18.
